Results 251 to 260 of about 123,443 (349)

Cannabinoids cool the intestine

, 2004
George Kunos, Pál Pacher
openalex   +1 more source

20.1 BEHAVIORAL, COGNITIVE, AND PSYCHOPHYSIOLOGICAL CHARACTERIZATION AND SHORT-TERM COURSE OF CANNABINOID- INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP) [PDF]

, 2019
Deepak Cyril D’Souza, K L Vidya, Sai Krishna Tikka, Justin Raj, Renu Gahalout, Patrick D. Skosnik, Christina Luddy, Nishant Goyal, Christoday R. J. Khess, Vinod Kumar Sinha, Daya Ram, Suhas Ganesh, Jose Cortes-Briones   +12 more
openalex   +1 more source

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 147-157, January 2026.
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM).
Andriy A. Gorbenko, Catherine M.K.E. de Cuba, Annika A. de Goede, Titiaan E. Post, Roman Bohoslavsky, Pamela K. Strugala, Jules A.A.C. Heuberger, Geert Jan Groeneveld   +7 more
wiley   +1 more source

Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review. [PDF]

Pharmaceuticals (Basel)
Marques BL, Lirio PHC, Vicente MA, Unzueta-Larrinaga P, Urigüen L, Campos AC.   +5 more
europepmc   +1 more source

A Comprehensive Exploration of the Multifaceted Neuroprotective Role of Cannabinoids in Alzheimer's Disease Across a Decade of Research

Petros Tyrakis, Christina Agridi, Malamati Kourti   +2 more
openalex   +2 more sources

Novel Peripherally Selective Cannabinoid Receptor 1 Neutral Antagonist Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice [PDF]

Lucas Laudermilk, Joel E. Schlosburg, Elaine A. Gay, Ann M. Decker, Aaron C. Williams, Rubica Runton, Vineetha Vasukuttan, Archana Kotiya, George Amato, Rangan Maitra   +9 more
openalex   +1 more source

The STRUCTUSTRUCTURAL AND DYNAMIC FEATURES OF ACUTE PSYCHOSIS DUE TO THE USE OF SYNTHETIC CANNABINOIDSRAL AND DYNAMIC FEATURES OF ACUTE PSYCHOSIS DUE TO THE USE OF SYNTHETIC CANNABINOIDS

, 2020
A.S. Subkhanberdina, Т.В. Клименко   +1 more
openalex   +1 more source

HS‐FET‐GC/MS‐Method Development and Validation for Analysis of 45 Terpenes—Creating a Complementary Tool for Comprehensive Profiling of Cannabis Flowers in Forensics

Drug Testing and Analysis, Volume 18, Issue 1, Page 118-138, January 2026.
Legalisation of medicinal cannabis leads to an increasing complexity of specific forensic questions. Terpenes, volatile hydrocarbons with modular construction principle of isoprene subunits, are suggested as second substance class alongside phytocannabinoids for classification of cannabis material.
Marica Hundertmark, Tanja Germerott, Cora Wunder   +2 more
wiley   +1 more source

A pilot study of dronabinol for the treatment of pain in sickle cell disease. [PDF]

Pilot Feasibility Stud
Curtis SA, Jhawar R, Bellis J, McCuskee S, Devine L, Roberts JD.   +5 more
europepmc   +1 more source

Data on individual metabolites of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans

, 2016
Shimpei Watanabe, Unnikrishnan Kuzhiumparambil, Zophia Winiarski, Shanlin Fu   +3 more
openalex   +1 more source